Is "The Next $52 Billion Startup" Stock Legit?

Welcome to my review of Mike Ward and Michael Robinson’s presentation on The Next $52 Billion Startup.

They claim to have unearthed a private pharmaceutical company that is working on cannabinoid-based drugs for an assortment of incurable diseases.

If things go well, they expect it to grow in value from $90 million to $52.5 billion, a 58,233% growth.

But is it realistic? Can you trust their investment advice?

I wrote this review to give you a quick summary of the presentation as well as my thoughts on whether it is legit.

Keep reading to learn more about the $52 billion-startup.

Before I start…

If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.

It’s helped me earn over $300,000 in the last 12 months alone:

Go here to see my no.1 recommendation for making money online

(This is a 100% free training)

The Next $52 Billion Startup Review

Table of Contents

Introduction to The Next $52 Billion Startup

“The Next $52 Billion Startup” is a presentation by Mike Ward and Michael Robinson in which they tout a pot company called Emerald Health Pharmaceuticals.

It is a private pharmaceutical company that is working on drugs that treat diseases that currently lack effective cures while affecting millions of people.

To achieve that, it creates drugs that have cannabinoids (derived from Cannabis) and other ingredients to treat previously incurable diseases. They enhance the healing properties of the natural molecules to increase their capabilities.

The National Institute of Cannabis Investors want you to invest in Emerald Health Pharmaceuticals, should it become successful. While it is currently valued at $90 million, they expect it to reach a market capitalization of $52.5 billion.

However, investing in a private company is not straightforward. For example, you need to be an accredited investor.

But Michael has found a way around it: Emerald Health Pharmaceuticals is doing its funding rounds through Regulation A+ funding, which enables you to invest even when you are not accredited as long as you restrict your investment to 10% of your annual income or net worth, whichever is greater.

There are two ways to earn massive returns on your investment should you invest in Emerald Health Pharmaceuticals:

If it is acquired, the company buying it out may pay more than its market value – something called acquisition premium – thus earning you a profit. For example, when Facebook acquired Oculus, it paid $2 billion rather than the market value of $250 million earning stakeholders a windfall.
If it goes public, your returns could be even greater depending on the success of the company. By their calculations, a $10,000 investment can morph into anywhere between $190,000 and $5.8 million depending on how successful the company is.

Who is behind The Next $52 Billion Startup?

Michael A. Robinson is a tech financial analyst. He is a Silicon Valley Veteran, where he has been active for over 35 years. He is a consultant and advisor to several Silicon Valley venture capital firms.

He enjoys access to high-profile industry insiders and was in attendance during the early meetings that helped launch cloud computing.

He publishes the Strategic Tech Investor, Nova-X Report, and Radical Technology Profits newsletters through Money Map Press.

How does The Next $52 Billion Startup Work?

To invest in Emerald Health Pharmaceuticals, you need to subscribe to the Cannabis Venture Syndicate.

When you become a member, you will receive three to five investment opportunities each year. Each has the potential to earn returns of 1,000% to 100,000%.

However, you have to agree to a non-disclosure once you join Cannabis Venture Syndicate because you gain access to private company information like expenditure, research costs, valuation projections, and revenue.

You also receive exclusive information on how to buy the shares of the private companies they recommend.

As soon as you join the Cannabis Venture Syndicate, they send you a copy of the Emerald Health Pharmaceuticals Due Diligence Package. It contains an analysis of their patented treatments, clinical trials, their projections, and potential exit opportunities if you invest.

In addition to that, your membership entitles you to:

Five private cannabis investment opportunities from Michael or any other National Institute of Cannabis Investors board member.
Optional text message alerts whenever a new investment opportunity comes up.
Monthly investment updates
Special email alerts when important events happen that can affect your holdings.
Membership to the Cannabis Venture Mastermind.
A short book called Private Investing Primer that sheds light on the intricacies of private investing.
Free tickets to the annual Cannabis Venture Syndicate retreat where you’ll meet other members of the club.

Subscription Fee

A one-year subscription goes for $1,950.

Is The Next $52 Billion Startup Legit?

The Next $52 Billion Startup is legit.

The recommendations that Michael and Mike make are based on current projections, pharmaceutical company data, and industry analysis. Since I was skeptical when I first encountered the presentation, I did my research and verified that the figures that they provide are true.

On top of that, an FDA approval such as the one Emerald is seeking could give it a monopoly over a multibillion-dollar market. This has happened before with other pharmaceutical companies.

Pros of The Next $52 Billion Startup

The drugs being developed by the startup have been proven to have low levels of toxicity and are effective. Those are two hurdles that many medical startups struggle with and it appears Emerald has cleared them.
Investing in the startup means you can make bank either when it is acquired or when it goes public.
Subscribing to Cannabis Venture Syndicate gives you access to investments that do not require you to be accredited, something that locks out a majority of individual investors.

Cons of The Next $52 Billion Startup

Emerald Health Pharmaceuticals is still unproven. It is a wildcard that could go either way; profitability or obscurity.
Its drugs could also fail to get FDA approval, which could render it a non-starter.

The Next $52 Billion Startup Verdict

When you become a member of Cannabis Venture Syndicate, you will gain access to private investments that few people ever gain access to. These are companies with good prospects that also allow non-accredited investors.

However, bear in mind that statistically, private companies are more likely to fail than proven, public companies. Therefore, you should prepare to live with the added risk if you decide to invest in Emeralds Health Pharmaceuticals or any other recommendations they send you.

Before you leave

If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.

It’s helped me earn over $300,000 in the last 12 months alone:

Go here to see my no.1 recommendation for making money online

(This is a 100% free training)